Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Mesoblast Limited (ASX: MSB) has marked a significant milestone with its RYONCIL (remestemcel-L) therapy, becoming the first FDA-approved mesenchymal stromal cell (MSC) treatment for any indication. The U.S. Centers for Medicare & Medicaid Services (CMS) has entered into a National Drug Rebate Agreement with Mesoblast, enabling nationwide coverage for paediatric patients suffering from steroid-refractory acute graft versus host disease (SR-aGvHD).
Treatment has now begun for the first three children under this initiative. RYONCIL is an off-the-shelf MSC therapy designed to combat severe inflammation and is administered over four weeks. Mesoblast, headquartered in Melbourne with operations in the U.S. and Singapore, is expanding its cell therapy pipeline across various conditions including adult SR-aGvHD, inflammatory bowel disease, heart failure, and chronic back pain. With a robust patent portfolio and global partnerships, the company is poised for commercial growth and broader therapeutic impact.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
